Production of hybridomas secreting monoclonal antibodies against the lympholine osteoclast activating factor.
The human lympholine osteoclast activating factor (OAF) is thought to be involved in several bone-destroying diseases. The current studies were designed to produce monoclonal antibodies against OAF for use in the subsequent design of immunoassays for OAF in clinical samples. Spleen cells from mice i...
Sábháilte in:
| Foilsithe in: | J Clin Invest |
|---|---|
| Príomhchruthaitheoirí: | , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
American Society for Clinical Investigation
1979
|
| Ábhair: | |
| Rochtain ar líne: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC372124/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/221547/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI109459 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|